GlassScriptPhysician profile
Gene D Cathey
NPI 1811918246
$7,893.05
in general payments reported to CMS, 2019-2025
38 companies · $896 in 2025
The $896 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,802 · 2020: $574 · 2021: $814 · 2022: $1,147 · 2023: $1,392 · 2024: $1,267 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,555.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,304.92 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $1,025.59 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $785.34 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $550.15 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $492.91 | 2019-2025 | |
| Glaxosmithkline, LLC. | $475.84 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $443.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $303.85 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $286.33 | 2019-2023 | Spravato |
| Astellas Pharma US INC | $275.10 | 2019-2025 | Veozah |
| Mylan Specialty L.P. | $249.22 | 2019-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $179.16 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $176.87 | 2023-2025 | Gemtesa |
| Vanda Pharmaceuticals INC. | $167.48 | 2019-2023 | Hetlioz |
| Exact Sciences Corporation | $120.82 | 2023-2025 | Cologuard Collection Kit |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gene Cathey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.